Erbitux’s enjoyment over RSA effect, Viread’s explosive upturn
‘Erbitux,’ the Merck’s targeted therapy for metastatic colorectal cancer, has well enjoyed the effect of the risk-sharing system.
Moreover, ‘Viread,’ the Gilead’s hepatitis B treatment, has shown an incredible growth by more than double along with the extension of the health insurance benefit. ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
